| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Aldeyra Therapeutics Inc. | ADX-2191 (methotrexate injection, USP) | Retinitis Pigmentosa | Phase 2/3 | Ongoing | Intravitreal | Genetic Disorder |
| Aldeyra Therapeutics Inc. | ADX-629 | Psoriasis / atopic asthma / COVID-19 | Phase 2 | Trial Discontinued | Oral | COVID-19 |
| Aldeyra Therapeutics Inc. | Ganetespib (ADX-1612) | Ovarian cancer | Phase 2 | Intravenous | Oncology | |
| Aldeyra Therapeutics Inc. | ADX-629 | Moderate / Acute Alcoholic Hepatitis | Phase 2 | Trial Discontinued | Oral | Gastroenterology |
| Aldeyra Therapeutics Inc. | Reproxalap (ADX-102) | Noninfectious anterior uveitis | Phase 3 | Ophthalmic | Opthalmic | |
| Aldeyra Therapeutics Inc. | Reproxalap (ADX-102) - (INVIGORATE-2) | Allergic conjunctivitis | NDA Filing | Data Released | Ophthalmic | Opthalmic |
| Aldeyra Therapeutics Inc. | Ganetespib (ADX-1612) | Ovarian cancer | Phase 2 | Intravenous | Oncology | |
| Aldeyra Therapeutics Inc. | Ganetespib (ADX-1612) | Post-transplant lymphoproliferative disorder | Phase 2 | Intravenous | Oncology |